Presentation is loading. Please wait.

Presentation is loading. Please wait.

The role of surgery in the modern management of dyspepsia

Similar presentations

Presentation on theme: "The role of surgery in the modern management of dyspepsia"— Presentation transcript:

1 The role of surgery in the modern management of dyspepsia
Mr Paras Jethwa Bsc MD FRCS Surrey & Sussex NHS Trust and Spire Gatwick Hospital


3 GORD Very significant modern disease High prevalence and incidence
Substantial drug budget Variable prescribing rationale (everyone in hospital) Correlation with obesity, diet, alcohol, coffee etc....

4 Mechanics of reflux

5 Treatment Options Lifestyle ( wine, obesity) PRN Antacids
PRN PPI Regular PPI (?BD ?Nexium) OGD (or sooner if red flag) Addition of antacid for breakthrough (Gaviscon Advanced) Addition of ranitidine for nocturnal symptoms ? Surgery - refer for pH/manometry

6 What about the guidelines?
significant number were mis-referred (i.e should have been urgent) 2% incidence of OG cancer 98% sensitive

7 Barrett’s

8 Intestinal Metaplasia
Both endoscopic and histological diagnosis Caused principally by uncontrolled acid reflux Confers an increased risk of oesophageal cancer of x Rapidly rising incidence Oesophageal Cancer 5th commonest cause of cancer mortality in the UK

9 Current treatment Treatment dose of a PPI Consider NSAIDs/ Aspirin
Surveillance Duration Interval Aneuploidy/tetraploidy Anti reflux surgery Oesophagectomy for HGD or Cancer

10 Surveillance limitations
Surveillance probably doesn't work Time consuming, inaccurate, distressing for patients, expensive Lack of an easily identifiable high risk group?

11 Current risk markers High Grade Dysplasia:
Patchy and easily missed On average HGD occupies only 1.3cm2/ 32cm2 of Barrett’s Variable Future Cancer risk: 13-59% develop Cancer within 5 years 40% of cancer patients not found to have prior HGD Aneuploidy: If no HGD or aneuploidy tiny risk (approaching 0%) of developing cancer in next 5 yrs (87% of patients) If aneuploidy risk of 38% If aneuploidy and HGD risk is 66% Panel of biomarkers: Ultimately this will be the answer Still in research setting


13 Long term effects of GORD

14 Anti reflux procedures
UK lags behind Australia and South Africa Determined by healthcare funding(?) Poorly accepted by some gastroenterologists Perception of a high risk/limited procedure May be underused in high risk groups and in younger patients Can offer a significant improvement in QoL

15 Surgical correction R CRUS OESOPHAGUS L CRUS

16 Effect of operation


18 Who should you consider referring?
Clear indication: Poorly controlled symptoms Hiatus hernia causing dysphagia +/- reflux Young patients with IM/marked oesophagitis Intolerant of conventional therapy Mass reflux Respiratory compromise Probably not for: Reasonable control with occasional flare-ups

19 Cost of therapy Drug Dose Cost (£, 28 days) Annual(£) Omeprazole 20mg
28.56 571.2 Lansoprazole 30mg £23.75 712.5 Pantoprazole 40mg £23.65 946 Rabeprazole £22.75 455 Esomeprazole £18.50 370 £28.56 1142.4

20 Is it cost effective? (1) The REFLUX Trial (first reported in BMJ 2009) “The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study”. Mean cost of Surgery: £ £4000 But - need to add cost of testing (OGD/pH/manometry) & loss of work etc. Significant QOL improvement at 12 months+ (SF36) (2) Systemic review 2011 Surg endoscopy Thijssen et al. Four publications were suitable, Jan 1990 to 2010 Surgery more expensive in n=3; Better QALY in n-=2, fewer symptoms n=1 C.E. - inconclusive - slight improvement in QALY

21 (3) Fundoplication vs medical management in adults for GORD - Cochrane review 2010
Four trials elligible n=1232 Significant improved QOL in surgical group % of patients have post op dysphagia Surgery risk uncommon but not without it’s risk Cost greater - based on 1st year of treatment only. Need to consider the long term effect of GORD Summary Improved QOL/QALY but ££ at one year

22 Surgical considerations
BMI <35 (men store fat at GOJ) woman up to 40 (Similar area to LAGB placement) Reasonable health/respiratory compromise No major motility issues (HRM/Ba swallow) Hiatus hernia/OGD proven reflux without pH studies Psychological onlay/effect of dietary change Physiological studies

23 pH Studies Only method of objectively proving reflux
In cases of odd symptoms/symptom correlation Pre/Post operative comparison Medico legal aspects Bravo or conventional systems

24 Results of surgery Three types of wrap commonly performed:
180< 270 < 360 Progressively better but increase risk of dysphagia & gas bloating Tension free wrap with good crural closure >85% report major improvement at 5 years pH retesting - no one with abnormal profile Not uncommon to return to some medication

25 Complications & SE Dysphagia - acute revision Gas bloating
GI dysmotility (non vagal) Recurrent symptoms Injury (GOJ/vagus/spleen/other)

26 Advanced technique - presented in Europe and UK
Largest series of mesh reinforced hiatal closures Common practice at ESH/Spire

27 Advances Improved training & simulation
Emphasis on dedicated laparoscopic service Improvement in HD systems/integrated theatre Anaesthesia and pain control Improved instrumentation Enhanced recovery protocols 3D laparoscopy/robots/NOTES/SILS

28 SASH 4 dedicated Laparoscopic specialists - laparoscopic surgery has become a speciality in itself. Very latest laparoscopic facilities and optics. SASH recognised as a high quality training centre amongst KSS trainees Links to Imperial College

29 The role of surgery in the modern management of dyspepsia
Mr Paras Jethwa Bsc MD FRCS Surrey & Sussex NHS Trust and Spire Gatwick Hospital

Download ppt "The role of surgery in the modern management of dyspepsia"

Similar presentations

Ads by Google